Panoramica dell'azienda
Cardiff Oncology, Inc. operates as a clinical-stage biotechnology entity dedicated to the development of novel therapeutic agents for the treatment of various malignancies within the United States market. The company functions within the broader healthcare sector, specifically targeting the specialized industry of biotechnology, which implies a focus on high-risk, high-reward research and development activities with significant regulatory hurdles. As of the latest available data, the entity holds a market capitalization of $108.02M and generates annual revenue of $593,000, supporting a workforce of 30 employees. These valuation and revenue figures indicate that Cardiff Oncology is a micro-cap biotech firm with a relatively small market footprint, where the current market cap represents a substantial multiple of its reported revenue, reflecting the speculative nature of investing in pre-commercial or early-stage clinical assets.
Salute finanziaria
The financial statements for the trailing twelve months reveal a revenue of $593,000, a net income of $-45,876,000, and an EBITDA of $-48,596,000. The substantial discrepancy between the minimal revenue and the massive negative net income highlights an aggressive cost structure typical of clinical-stage biotechs, where expenditures on research, development, and clinical trials far outweigh current sales proceeds. The company reports a free cash flow of $-19,617,000, indicating a continuous cash burn that necessitates external capital raises or the utilization of existing cash reserves to fund ongoing operations. Margin analysis shows a gross margin of 0.0%, an operating margin of -3221.0%, and a profit margin of 0.0%, figures that collectively underscore the intense leverage of fixed R&D costs against negligible sales volume at this stage of development. On the balance sheet, the company holds $58.30M in cash against $832,000 in debt, supported by a debt-to-equity ratio of 1.83, suggesting a leveraged position where significant equity capital is required to support the debt load relative to book value. Liquidity is further supported by a current ratio of 3.67, which indicates a robust short-term ability to cover obligations despite the cash burn rate. Return metrics show a return on equity of -71.5% and a return on assets of -38.5%, revealing that management is currently generating negative returns on both shareholder equity and total assets due to the pre-commercial status of the lead drug candidate Onvansertib.
Valutazione del valore
Valuation multiples for Cardiff Oncology present a complex picture due to the lack of profitability, with a trailing P/E ratio of N/A and a forward P/E of -2.26. The negative forward P/E and the absence of a trailing P/E imply that earnings are currently negative and that future earnings trajectories remain uncertain until clinical milestones are achieved or commercialization begins. The price-to-book ratio stands at 2.38, indicating that the market values the company at more than double its book value, a premium often attributed to the potential value of its intellectual property and pipeline assets rather than current earnings power. Alternative valuation metrics such as a price-to-sales ratio of 182.15 and an EV/EBITDA of -1.04 further emphasize that the stock is priced based on speculative growth potential rather than operational performance or cash flow generation. The stock's price range over the last year has oscillated between a 52-week low of $1.48 and a 52-week high of $4.56, providing a trading band within which the market prices in varying degrees of optimism regarding the company's clinical progress. The beta of 1.42 indicates that the stock exhibits high price volatility relative to the broader market, moving with greater intensity than the S&P 500, which is characteristic of small-cap biotechnology stocks sensitive to clinical trial outcomes and regulatory news.
Growth & Income
Growth metrics highlight a revenue growth rate of 60.9% year-over-year, while earnings growth is listed as N/A due to the company's continued losses. The fact that earnings growth is not available while revenue expands suggests that the company is in a phase where top-line expansion from new indications or partnerships is occurring, yet the bottom line remains deeply negative due to the inherent costs of drug development. As the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, all available capital is necessarily reinvested back into the business to fund clinical trials and operational expansion rather than being distributed to shareholders. Consequently, the overall growth and income profile of Cardiff Oncology is characterized by aggressive top-line expansion funded entirely by internal cash reserves and external financing, with no current income generation for investors.